Oxmiq Labs Inc.™: Re-Architecting the GPU Stack: From Atoms to Agents™
Oxmiq Labs Inc., the all-new GPU software and IP startup founded by one of the world’s top GPU architects and visionaries, Raja Koduri, emerges from stealth after two years of intensive IP development. Raja has assembled a world-class team of GPU and AI architects with over 500 years of combined experience, hundreds of patents, and a collective track record of generating more than $100B in revenue at prior companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805908309/en/
Raja Koduri Founder / CEO Oxmiq Labs Inc.
The Opportunity:
Modern computing has fundamentally shifted toward multimodal experiences where text, audio, video, images, and 3D environments seamlessly interact, establishing GPU architecture as the cornerstone of this transformation. Unlike fixed-function AI accelerators that handle specific tasks, GPUs provide the general-purpose computational flexibility required for these diverse modalities while maintaining deep integration with mainstream operating systems through standardized APIs and unified memory models. This architectural advantage positions GPUs as the essential compute engine for both current applications and the emerging landscape of multimodal AI, where heterogeneous workloads must be processed in harmony.
OXMIQ™'s licensable GPU IP rearchitects the GPU from first principles incorporating breakthrough technologies including nano agents in silicon leveraging RISC-V cores, near-memory and in-memory computing, and light transport. OXMIQ delivers solutions that balance multimodal computing flexibility with the radical performance improvements required for next-generation graphics and AI workloads for its customers.
Software First:
Learning from decades of industry evolution, OXMIQ embraces a Software First strategy that prioritizes developer experience through a comprehensive software stack compatible with bothOXMIQIP-based silicon and third-party GPU and AI accelerator platforms.
OXCapsule™, OXMIQ's unified software ecosystem, abstracts away hardware complexity to provide frictionless deployment across diverse computing platforms, eliminating the configuration challenges that traditionally plague heterogeneous environments.
A flagship component, OXPython™, enables Python-based NVIDIA® CUDA™ AI applications to execute seamlessly on non-NVIDIA hardware without code modification or recompilation. Launching initially on Tenstorrent's AI platform later this year with multiple vendor integrations in progress, OXPython demonstrates OXMIQ's commitment to breaking down hardware silos and accelerating the democratization of high-performance computing across the industry.
“We’re excited to partner with OXMIQ on their OXPython software stack,” said Jim Keller, CEO of Tenstorrent™. “OXPython’s ability to bring Python® workloads for CUDA to AI platforms like Wormhole™ and Blackhole™ is great for developer portability and ecosystem expansion. It aligns with our goal of letting developers open and own their entire AI stack.”
The OXMIQ Breakthrough:
Beyond software, OXMIQ delivers a complete GPU hardware IP stack that powers silicon solutions scaling from Physical AI in edge devices and autonomous robots to enterprise edge infrastructure and zettascale data centers. Their scalable GPU core, OXCORE™, integrates scalar, vector, and tensor compute engines in a modular architecture customizable for specific workloads, enabling nano-agents, native Python acceleration, and compatibility with SIMD/CUDA paradigms.
OXCORE scales seamlessly from single core for compact Physical AI applications to thousands of cores for data centers via the OXQUILT™ chip-let architecture. Through OXQUILT, customers can configure optimal ratios of compute, memory and interconnect for their needs and achieve significant reduction in time to market, R&D and production costs v/s current industry standard methodologies.
Capital Efficiency & Market Traction:
OXMIQ has raised $20 million in seed funding from prominent technology investors, including strategic players in mobile and AI silicon such as MediaTek®, and has recorded its first round of software revenue. With its licensing-first model, OXMIQ avoids the heavy capital requirements of chip startups that depend on expensive EDA tools and physical tape-outs — delivering outstanding capital efficiency.
“OXMIQ has an impressive bold vision and world-class team,” said Lawrence Loh, SVP of MediaTek“The company’s GPU IP and software innovations will drive a new era of compute flexibility across devices – from mobile to automotive to AI on the edge.”
Mihira™:
After co-founding Mihira two years ago with Shobu Yarlagadda and SS Rajamouli, Raja Koduri has transitioned out of day-to-day operations at Mihira to focus full-time on running OXMIQ. Raja now acts as a strategic advisor to Mihira Visual Labs™, which is led by CEO Shobu Yarlagadda. OXMIQ holds a minority stake in Mihira and will continue to support its growth through foundational agentic and GPU IP technologies that power Mihira’s cinematic AI platform.
“Raja’s early contributions to Mihira helped shape our foundational vision of cinematic AI. Now, with OXMIQ, he and his team are building the deep-tech infrastructure that powers our next chapter,” said Shobu Yarlagadda, Co-Founder and CEO of Mihira Visual Labs™, and acclaimed producer of the Baahubali film series. “As we scale Mihira into a global creative platform, we’re thrilled to continue our close collaboration with OXMIQ and integrate their agentic GPU innovations into our storytelling stack.”
To learn more about licensing, investment, or career opportunities visit us on the web at oxmiq.ai.
Trademark Acknowledgments
NVIDIA and CUDA are trademarks or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Python is a registered trademark of the Python Software Foundation. Tenstorrent, Wormhole, and Blackhole are trademarks of Tenstorrent Inc. MediaTek is a registered trademark of MediaTek Inc. All other product names, trademarks, and registered trademarks are property of their respective owners and are used for identification purposes only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805908309/en/
Contacts
Media Contact mark.hirsch@oxmiq.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom